Increased sympathetic nervous system impairs prognosis in lung cancer patients: a scoping review of clinical studies.

Autor:	Garramona FT; University of Sorocaba, Sao Paulo, 18023-000, Brazil.; School of Physical Education & Sport, University of Sao Paulo, Sao Paulo, 05508-30, Brazil., Cunha TF; School of Physical Education & Sport, University of Sao Paulo, Sao Paulo, 05508-30, Brazil.; Paulista University, Sao Paulo, 01533-000, Brazil., Vieira JS; School of Physical Education & Sport, University of Sao Paulo, Sao Paulo, 05508-30, Brazil., Borges G; School of Physical Education & Sport, University of Sao Paulo, Sao Paulo, 05508-30, Brazil., Santos G; School of Physical Education & Sport, University of Sao Paulo, Sao Paulo, 05508-30, Brazil., de Castro G; Cancer Institute of the State of Sao Paulo (ICESP), Clinical Hospital of Medical College - University of Sao Paulo, Sao Paulo, 01246-000, Brazil., Ugrinowitsch C; School of Physical Education & Sport, University of Sao Paulo, Sao Paulo, 05508-30, Brazil., Brum PC; School of Physical Education & Sport, University of Sao Paulo, Sao Paulo, 05508-30, Brazil.
Jazyk:	angličtina
Zdroj:	Lung cancer management [Lung Cancer Manag] 2024 Jan 16; Vol. 12 (4), pp. LMT63. Date of Electronic Publication: 2024 Jan 16 (Print Publication: 2023).
DOI:	10.2217/lmt-2023-0006
Abstrakt:	Aim: To summarize current knowledge, gaps, quality of the evidence and show main results related to the role of the autonomic nervous system in lung cancer. Methods: Studies were identified through electronic databases (PubMed, Scopus, Embase and Cochrane Library) in October 2023, and a descriptive analysis was performed. Twenty-four studies were included, and most were observational. Results: Our data indicated an increased expression of β-2-adrenergic receptors in lung cancer, which was associated with poor prognosis. However, the use of β-blockers as an add-on to standard treatment promoted enhanced overall survival, recurrence-free survival and reduced metastasis occurrence. Conclusion: Although the results herein seem promising, future research using high-quality prospective clinical trials is required to draw directions to guide clinical interventions. Competing Interests: Competing interests disclosure The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. (© 2024 Future Medicine Ltd.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu